Navigation Links
Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
Date:12/21/2007

otech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the Phase 1a/Ib U.K. combination REOLYSIN(R) and radiation clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
(Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
(Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
(Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2
... CALGARY, Oct. 26 /PRNewswire-FirstCall/ - SemBioSys Genetics ... of therapeutic,proteins for metabolic and cardiovascular diseases, ... scientific poster and abstract at the Seventh ... by the Diabetes,Technology Society. The poster will ...
... ECG services, RESEARCH TRIANGLE PARK, N.C., Oct. ... H. Cabell, M.D., MHS,FACC, an expert cardiologist and ... group in Global Clinical Development Services,(CDS). In addition ... for Quintiles ECG Services. Cabell comes to ...
... Pharmasset, Inc.,(Nasdaq: VRUS ) management will be presenting at ... Rodman & Renshaw 9th Annual Healthcare Conference being ... Hotel in New York City. Schaefer ... will provide an overview of the company on Tuesday, ...
Cached Biology Technology:SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting 2Expert Cardiologist Joins Quintiles Medical Group 2Pharmasset to Present at Three Investor Conferences in November 2007 2
(Date:7/10/2014)... 2014 Fingerprint Cards, (FPC,s) ... win (DW). An Asian OEM has selected FPC1021 for a ... in August 2014.   FPC is proud to ... a planned date for start of mass production in August ... SEK 5M, for delivery in the first half of July. ...
(Date:7/10/2014)... An international team ... step of photosynthesis in action for the first time. The ... used the world,s most powerful X-ray flashlight at the US ... molecular complex called photosystem II as it splits water into ... earth,s atmosphere. The researchers report their results in the scientific ...
(Date:7/10/2014)... Marshall Institute for Interdisciplinary Research (MIIR) and the ... today announced they will be partnering with an ... , Under the agreement with Shanghai-based HD Biosciences ... costs and risks of discovery and development of ... any intellectual property and commercialization rights to products ...
Breaking Biology News(10 mins):FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3Marshall University to partner with international company in drug development venture 2
... A team of scientists studying the effects of ... its research published in the February issue of the ... said the study,s lead investigator. The study quantified ... the use of electron-beam irradiation. "The purpose of ...
... have led to the discovery of a new species of ... la Muerte". The discovery was made thanks to molecular data ... the overall knowledge of plant lice (one of the most ... 20%. The study was published in the open access journal ...
... DNA sequencing to detect genetic mutations can aid ... Current methods of testing DNA samples, Sanger sequencing ... difficult or impossible to interpret. Scientists at the ... free software program, Pyromaker, that can more accurately identify ...
Cached Biology News:Study shows electron-beam irradiation reduces virus-related health risk in lettuce, spinach 2Study shows electron-beam irradiation reduces virus-related health risk in lettuce, spinach 3A new species of bamboo-feeding plant lice found in Costa Rica 2New virtual tool may provide more accurate diagnosis of genetic mutations 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Rabbit Anti-Mouse Ym1 Polyclonal Antibody,...
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... Analysis of large numbers of samples may be ... which requires minimum operator attention. System ... software and interface CE 4900. The elegant, ... in Windows XP and Windows 98 and 2000., ...
Biology Products: